Types of Vascular Anomalies |
Types of Vascular
Anomalies |
Types of Vascular Anomalies |
Vascular Tumors |
|
|
KHE/Tufted Angioma a
|
24 (8) |
|
Epithelioid Hemangioendothelioma |
8 (3) |
|
Vascular Malformations |
|
|
Complex Lymphatic Anomaly b
|
7 (2) |
|
PIK3CA-Related Overgrowth Spectrum |
18 (6) |
|
Slow Flow Vascular Malformation |
60 (21) |
|
Arteriovenous Malformation |
3 (1) |
|
Blue Rubber Bleb Nevus Syndrome |
1 (<1) |
|
Multiple Vascular Anomalies |
169 (58) |
|
Type of Infection c (n=315 total infections) |
Type of Infection c (n=315 total
infections) |
Type of Infection c (n=315
total infections) |
Upper Respiratory Infection / ”Viral Infection” d
|
137 (54) |
|
Pneumonia e
|
52 (20) |
|
Cutaneous Infection |
20 (8) |
|
Gastroenteritis |
14 (5) |
|
Urinary Tract Infection/Pyelonephritis |
7 (3) |
|
Lymph Gland Infection |
11 (4) |
|
Bacteremia |
4 (1) |
|
Osteomyelitis/Septic Arthritis |
3 (1) |
|
Meningitis |
2 (<1) |
|
Herpes Reactivation |
2 (<1) |
|
Infectious thrombophlebitis |
1 (<1) |
|
Culture Negative Sepsis |
1 (<1) |
|
CMV |
1 (<1) |
|
CTCAE Grade of Infections f |
CTCAE
Grade of Infections f |
|
1 to 2 |
194 (66) |
|
3 to 4 |
95 (32) |
|
5 |
6 (2) |
|
Sirolimus Trough (Target or Actual) g |
Sirolimus Trough (Target or Actual)
g |
|
2 to 5 |
21 (9) |
|
5 to 10 |
49 (20) |
|
5 to 15 |
5 (2) |
|
10 to 15 |
159 (65) |
|
>15 |
11 (4) |
|
Antibiotic Prophylaxis h |
Antibiotic
Prophylaxis h |
|
Penicillin |
1 (<1) |
|
PJP Prophylaxis |
175 (80) |
|
None |
42 (19) |
|